Enliven Therapeutics ELVN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $20.69M-16.9% | $21.25M+2.5% | $18.23M-14.3% | $21.49M+14.2% | $24.9M+24.7% | ||
| $7.14M+5.0% | $13.04M+111% | $6.87M+18.3% | $7.09M+22.8% | $6.8M+13.0% | ||
| $27.82M-12.2% | $34.29M+27.5% | $25.1M-7.3% | $28.58M+16.2% | $31.69M+22.0% | ||
| $27.82M-12.2% | $34.29M+27.5% | $25.1M-7.3% | $28.58M+16.2% | $31.69M+22.0% | ||
| -$27.82M+12.2% | -$34.29M-27.5% | -$25.1M+7.3% | -$28.58M-16.2% | -$31.69M-22.0% | ||
| $4.2M+31.3% | $4.62M+24.3% | $4.95M+28.9% | $3.25M-20.4% | $3.2M-1.7% | ||
| $4.2M+33.2% | $4.62M+24.3% | $4.95M+26.5% | $3.25M-30.2% | $3.15M-3.1% | ||
| -$23.63M+17.2% | -$29.67M-28.0% | -$20.15M+13.0% | -$25.34M-27.0% | -$28.54M-25.5% | ||
| -$0.38+33.3% | -$0.48-4.3% | -$0.32+33.3% | -$0.49-19.5% | -$0.57-5.6% | ||
| -$0.38+33.3% | -$0.48-4.3% | -$0.32+33.3% | -$0.49-19.5% | -$0.57-5.6% | ||
| 62.8M+25.5% | 56.7M+20.4% | 62.1M+28.6% | 52.1M+8.4% | 50.1M+19.0% | ||
| 62.8M+25.5% | 56.7M+20.4% | 62.1M+28.6% | 52.1M+8.4% | 50.1M+19.0% | ||
| $4.2M+31.3% | $4.62M+24.3% | $4.95M+28.9% | $3.25M-20.4% | $3.2M-1.7% | ||
| -$24.34M+14.9% | -$29.55M-26.5% | -$19.75M+13.3% | -$25.5M-27.3% | -$28.62M-24.8% | ||
| -$716K-908% | $113K+160% | $398K+4.5% | -$161K-87.2% | -$71K+63.4% | ||
| $0+100% | $0— | $0— | -$2K-100% | -$47K-4,600% | ||
| -$27.82M+12.2% | -$34.29M-27.5% | -$25.1M+7.3% | -$28.58M-16.2% | -$31.69M-22.0% | ||
| -$27.81M+12.0% | -$34.24M-27.7% | -$25.03M+7.2% | -$28.5M-16.2% | -$31.62M-22.0% | ||
| -$27.81M+12.0% | -$34.24M-27.7% | -$25.03M+7.2% | -$28.5M-16.2% | -$31.62M-22.0% | ||
| -$27.82M+12.2% | -$34.29M-27.5% | -$25.1M+7.3% | -$28.58M-16.2% | -$31.69M-22.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Enliven Therapeutics profitable?
- Enliven Therapeutics is not currently profitable: it reported a net loss of $98.8M over the trailing twelve months.
- What is Enliven Therapeutics's earnings per share?
- Enliven Therapeutics's diluted EPS over the trailing twelve months is $-1.67.
- Where does Enliven Therapeutics's income statement data come from?
- Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.